A Study of Remternetug (LY3372993) in Healthy Participants

Launched by ELI LILLY AND COMPANY · Jul 8, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a medicine called remternetug to see how it behaves in the body when given as a single injection under the skin. The researchers are comparing two different ways of giving the injection—using an autoinjector (a device that gives the shot automatically) or a prefilled syringe (a regular injection). They want to find out how much of the medicine enters the bloodstream and how long it stays in the body with each method.

The study is looking for healthy adults who are between 18 and 74 years old and have a body weight in a normal range based on their height. To join, participants need to be generally healthy with no serious medical problems, especially no heart, lung, liver, or brain issues, and they must not be taking other medications that could interfere with the study. The whole study will last about 155 days, and participants will be closely monitored throughout this time. If you join, you can expect medical check-ups, blood tests, and possibly MRI scans to ensure your safety and to help researchers understand how the medicine works in the body.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Are overtly healthy as determined by medical evaluation, including medical history, physical examination, laboratory tests, and cardiac monitoring.
• • Have a body mass index within the range of 18.0 to 34.0 kilograms per meter squared (kg/m2) (inclusive).
• Exclusion Criteria:
• • Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs or of constituting a risk when taking the study drug or of interfering with the interpretation of data.
• • Have evidence of significant active neuropsychiatric disease, as determined by the investigator.
• • Have a personal or family history of early onset AD (AD diagnosed prior to 65 years of age).
• • Contraindication to MRI, including claustrophobia that cannot be managed with low-dose sedatives or the presence of contraindicated metal (ferromagnetic) implants/cardiac pacemakers.
• • Intend to use over-the-counter or prescription medication, including herbal medications and traditional medications, with the exception of vitamin/mineral supplements, any hormone replacement therapy, and/or thyroid replacement therapy, within 7 days prior to dosing and for the duration of the study.
• • Have a brain MRI that demonstrates any clinically significant findings that, in the opinion of the investigator, may impact the participant's ability to safely participate in the study.